The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

Tildrakizumab Promising for Plaque Psoriasis; FDA Approves Adalimumab to Treat Panuveitis

July 20, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Tildrakizumab Promising for Plaque Psoriasis
Tildrakizumab (MK-3222) is an interleukin (IL)-23p19 inhibitor antibody designed to selectively block IL-23. The treatment has met its primary safety and efficacy endpoints in two Phase 3 clinical trials in patients with moderate to severe plaque psoriasis.1 In these placebo-controlled studies, the co-primary efficacy endpoints were: 1) the percentage of patients achieving a Psoriasis Area Sensitivity Index (PASI) 75 response at Week 12, and 2) the percentage of patients with a Physician’s Global Assessment (PGA) score of clear or minimal with at least a two-grade reduction from baseline at Week 12. Both measurements were compared with placebo-treated patients. There were no new safety signals.

You Might Also Like
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
  • Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
  • Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA
Also By This Author
  • FDA Approves the Biosimilar Hadlima (Adalimumab-bwwd)

The second of the two studies (Study MK-3222-011) also had a comparator arm of patients using etanercept. A secondary efficacy endpoint of the study was the comparison of 200 mg tildrakizumab and etanercept on PASI 75 and PGA. The 200 mg dose of tildrakizumab was superior to etanercept on both PASI 75 and PGA endpoints at Week 12. A dose of 100 mg tildrakizumab also showed superiority to etanercept, but only on the PASI 75.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

FDA Approves Adalimumab for Non-Infectious Panuveitis
Adalimumab (Humira) has garnered its 10th FDA-approved indication.2 It has been approved for treating non-infectious intermediate, posterior and panuveitis. This approval marks the first and only FDA-approved, non-corticosteroid treatment for adults with non-infectious intermediate, posterior and panuveitis.

By blocking tumor necrosis factor alfa (TNF-α), inflammation in uveitis is diminished. This approval is based on the results of two Phase 3 studies in adults, VISUAL-I and VISUAL-II. Patients were randomized 1:1 and treated with a subcutaneous injection of 80 mg adalimumab as a baseline-loading dose followed by 40 mg adalimumab at Week 1 and 40 mg adalimumab every other week for up to 80 weeks.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The primary endpoint in the VISUAL-I and VISUAL-II studies was time to treatment failure, defined as having one or more of the following components present in at least one eye: increase in anterior chamber cells or vitreous haze, new chorioretinal or vascular lesions, or decrease in visual acuity. In VISUAL-I, the median time to treatment failure was prolonged by 87% (three months for placebo-treated patients vs. 5.6 months for adalimumab-treated patients). In VISUAL-II, the median time to treatment failure was 8.3 months for placebo-treated patients. But researchers were unable estimate the time to treatment failure (>18 months) for adalimumab-treated patients because more than half of these patients did not experience a treatment failure. No new safety risks were identified in these patients.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, etanercept, FDA, Food and Drug Administration, panuveitis, plaque psoriasis, tildrakizumab

You Might Also Like:
  • FDA Approves Valeant’s Drug to Treat Plaque Psoriasis
  • Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
  • Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA
  • Revised Application Expected for IV Meloxicam; Plus EU Approves Tildrakizumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.